There is a need for efficacious, convenient treatments with long-term tolerability for patients with relapsed/refractory multiple myeloma (RRMM). This phase 2 study evaluated the all-oral combination of ixazomib, cyclophosphamide and dexamethasone (ICd). Patients with RRMM received ixazomib 4 mg and cyclophosphamide 300 mg/m 2 on days 1, 8
Summary
There is a need for efficacious, convenient treatments with long-term tolerability for patients with relapsed/refractory multiple myeloma (RRMM). This phase 2 study evaluated the all-oral combination of ixazomib, cyclophosphamide and dexamethasone (ICd). Patients with RRMM received ixazomib 4 mg and cyclophosphamide 300 mg/m 2 on days 1, 8
and 15, and dexamethasone 40 mg on days 1, 8, 15 and 22 in 28-day cycles. The primary endpoint was overall response rate (ORR). Seventyeight patients were enrolled (median age 63Á5 years). At data cut-off, patients had received a median of 12 treatment cycles; 31% remained on treatment. ORR was 48% [16% very good partial response or better (≥VGPR)]. ORR was 64% and 32% in patients aged ≥65 and <65 years (25% and 16% ≥VGPR), respectively. At a median follow-up of 15Á2 months, median progression-free survival (PFS) was 14Á2 months, with a trend towards better PFS in patients aged ≥65 years vs. <65 years (median 18Á7 months vs. 12Á0 months; hazard ratio 0Á62, P = 0Á14). ICd was well tolerated. The most common treatment-emergent adverse events were diarrhoea (33%), nausea (24%), upper respiratory tract infection (24%), and thrombocytopenia (22%); 10 patients (13%) had peripheral neuropathy (one grade 3). This study is registered at ClinicalTrials.gov (NCT02046070).
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Treatment approaches for multiple myeloma (MM) have changed dramatically in the past 15 years due to increasing numbers of drugs, as well as more widespread use of combination regimens and prolonged treatment strategies (Kumar et al, 2017a) . In this changing treatment landscape, proteasome inhibitors (PIs) remain an important component of therapeutic regimens for both relapsed/refractory MM (RRMM) and newly diagnosed MM (NDMM), with demonstrated efficacy alone as well as in combination with a variety of different anti-myeloma drugs (Lonial & Boise, 2011;  research paper
First published online 20 November 2018 doi: 10.1111/bjh.15679 Moreau et al, 2012; Schlafer et al, 2017) . In particular, the combinations of bortezomib with alkylating agents are highly effective regimens. Bortezomib in combination with melphalan and prednisone is a commonly used regimen for patients with NDMM not eligible for transplant (San Miguel et al, 2008) , and bortezomib in combination with cyclophosphamide and dexamethasone (VCd) has demonstrated efficacy both as induction therapy prior to autologous stem cell transplantation (SCT) and for patients with relapsed disease (Kumar et al, 2012; Reeder et al, 2014; Moreau et al, 2015; Reece et al, 2016) . Bortezomib-based regimens, however, are associated with high rates of peripheral neuropathy (PN) and may present a challenge to patients due to the requirement for once-or twice-weekly clinic visits for parenteral administration (Lonial & Boise, 2011; Moreau et al, 2012; Richardson, 2014) . Thus, there is a need for alternative regimens that can improve efficacy in patients later in their treatment course, without sacrificing tolerability and quality of life (QoL). In particular, there is a need for further treatment options for elderly/frail patients and for those in whom immunomodulatory drugs, such as lenalidomide, have failed or are contra-indicated. Ixazomib, a novel, oral, small-molecule inhibitor of the 20S proteasome subunit, was the first oral PI to enter the clinic and, on the basis of results from the phase 3, placebocontrolled TOURMALINE-MM1 trial (Moreau et al, 2016) , is approved by the US Food and Drug Administration and European Medicines Agency in combination with lenalidomide and dexamethasone for patients who have received at least one prior line of therapy https://www.accessdata.fda. gov/drugsatfda_docs/label/2015/208462lbl.pdf). In addition to the demonstrated efficacy in combination with lenalidomide and dexamethasone (Kumar et al, 2014a; Moreau et al, 2016) , ixazomib has shown activity in RRMM as a single agent as well as in combination with dexamethasone (Kumar et al, 2014b (Kumar et al, , 2015 Richardson et al, 2014) . Given the efficacy of the VCd combination, it was important to examine whether an all-oral combination of ixazomib, cyclophosphamide and dexamethasone (ICd) can offer similar activity, with better tolerability and a more convenient administration. ICd has been studied in NDMM, demonstrating excellent efficacy with a good safety profile. This open-label, multicentre, phase 2 study (NCT02046070) assessed the safety and efficacy of ICd in patients with RRMM.
Methods

Patients
Patients aged 18 years or older with a diagnosis of RRMM after 1-3 prior lines of therapy were enrolled. Eligible patients had measurable disease, Eastern Cooperative Oncology Group performance status 0-2, and adequate haematological, hepatic and renal function. Bortezomib-refractory patients were excluded [defined as progressive disease (PD) during, or within 60 days of last dose of previous treatment]. Patients with grade ≥2 PN or grade 1 PN with pain, those refractory to PIs, and those requiring systemic treatment with strong inhibitors of CYP1A2, strong inhibitors of CYP3A, or strong CYP3A inducers of CYP3A, or use of Ginkgo biloba or St. John's wort within 14 days before first dose of study treatment were excluded. Detailed eligibility criteria are provided in the Supporting Information. All patients provided written, informed consent prior to participation in the trial.
Study design and objectives
This open-label, phase 2 study in patients with RRMM was part of a three-arm study that evaluated the safety, tolerability and efficacy of weekly oral ixazomib combined with cyclophosphamide and dexamethasone in adult patients with MM. Two arms of the study enrolled patients with NDMM and one arm enrolled patients with RRMM. Here, we report only on the patients with RRMM; and results for patients with NDMM will be reported separately (Dimopoulos et al, 2018) . The study was conducted at six sites in Australia, five sites in Greece, three sites in Sweden, four sites in Poland and five sites in the United States of America. Review boards at all participating institutions approved the study, which was conducted according to the Declaration of Helsinki, the International Conference on Harmonization Guidelines and the Guidelines for Good Clinical Practice. The study was registered at www.clinicaltrials.gov as NCT02046070.
Ixazomib was administered orally at 4 mg daily on days 1, 8 and 15 of a 28-day cycle, along with cyclophosphamide 300 mg/m 2 orally on days 1, 8 and 15, and dexamethasone 40 mg orally on days 1, 8, 15 and 22. In patients over 75 years of age, the dexamethasone dose was reduced to 20 mg. Patients were treated until PD, death or unacceptable toxicity. Dose modifications of all three drugs were permitted for toxicities suspected to be related to the specific drugs. A safety leadin evaluation was performed after seven patients had completed one cycle to evaluate toxicity. Dose-limiting toxicities (DLTs), if any, observed in the first six patients were used to determine the safety and overall tolerability of the regimen and the feasibility of continued recruitment to the study. The primary objective was to determine the overall response rate [ORR; ≥partial response (PR)] with ICd in patients with RRMM. Secondary objectives included determination of safety, complete response (CR) and very good partial response (VGPR) rates, and measures of response durability [time to response (TTR), duration of response (DOR), time to progression (TTP), progression-free survival (PFS)] and plasma pharmacokinetics of ixazomib when administered in combination with cyclophosphamide and dexamethasone.
Assessments
Responses were assessed by the investigators using International Myeloma Working Group uniform criteria (Kumar Table I . Demographics, baseline characteristics and prior therapies in patients receiving ICd, overall and by age at study entry. (53) 23 (56) 18 (49) 0Á51 White, n (%) 74 (95) 38 (93) 36 (97) 0Á63 ECOG PS, n (%) 0 38 (49) 21 (51) 17 (46) 0Á82 1 33 (42) 17 (41) 16 (43) 2 7 (9) 3 (7) 4 (11) High-risk cytogenetics, n (%)
6 (8) 5 (12) 1 (3)
0Á12
MM disease type, n (%) IgG 46 (59) 21 (51) 25 (68)
0Á22
IgA 11 (14) 6 (15) 5 (14) Light chain only 18 (23) 13 (32) 5 ( (24) 8 (20) 11 (30) III 21 (27) 10 (24) 11 (30) Creatinine clearance <60 ml/min 18 (23) 2 (5) 16 (43)
<0Á0001
Median time from diagnosis, months (range)
Lines of prior therapy, n (%) 1 30 (38) 11 (27) 19 (51) 0Á026 2/3
48 (62) 30 (73) 18 (49) Best response to prior therapy, n (%) ‡ CR 30 (38) 17 (41) 13 (35) 0Á71 PR 43 (55) 21 (51) 22 (59) SD 3 (4) 2 (5) 1 (3) Refractory to any prior line, n (%)
15 (19) 8 (20) 7 (19)
0Á95
Prior bortezomib, n (%)
45 (58) 31 (76) 14 (38)
0Á0007
Prior carfilzomib, n (%)
3 (4) 1 (2) 2 (5)
0Á50
Prior immunomodulatory drug, n (%)
65 (83) 32 (78) 33 (89) 0Á19 Thalidomide 41 (53) 20 (49) 21 (57) 0Á48 Lenalidomide 38 (49) 21 (51) 17 (46) 0Á64 Prior SCT 50 (64) 34 (83) 16 (43 (14) 2 (6) CR, complete response; ICd, ixazomib, cyclophosphamide and dexamethasone; IMWG, International Myeloma Working Group; ORR, overall response rate; PD, progressive disease; PR, partial response; SD, stable disease; VGPR, very good partial response. *Three patients in total had responses that could not be confirmed on a subsequent assessment (patients aged <65 n = 1, patients aged ≥65 n = 2). 
Statistical analysis
The sample size was calculated by using one group chisquare test based on the ORR rate following an ixazomib combined treatment regimen. With 71 response-evaluable patients, there was 80% power to test a null hypothesis ORR rate of 60% and an alternative hypothesis ORR rate of 72% at 1-sided significant level of a = 0Á10. The safety population included all patients who received ≥1 dose of any study drug and was used for safety, PFS, TTP and QoL analyses. The DLT-evaluable population included patients in the safety lead-in cohort who received all doses of ixazomib and ≥80% of the cyclophosphamide dose during Cycle 1, or experienced a DLT in Cycle 1. Per protocol, response-evaluable patients were those who received ≥2 out of the three planned ixazomib doses during Cycle 1 (minimum required ixazomib exposure), had measurable disease at baseline and ≥1 postbaseline response assessment. The response-evaluable population was used for analyses of response rates, TTR and DOR. The Kaplan-Meier method was used to evaluate TTR, DOR, TTP and PFS. The pharmacokinetic-evaluable population included patients in the safety lead-in cohort who had sufficient dosing data and ixazomib concentration-time data to permit calculation of pharmacokinetic parameters using Phoenix WinNonlin version 6.3 (Pharsight, St. Louis, MO, USA). Statistical analyses were performed using SAS software version 9.2 (SAS Institute Inc., Cary, NC, USA). Non-compartmental analysis methods were used to estimate pharmacokinetic parameters. A stepwise Cox model was used to identify potential predictive factors for PFS using relevant demographic and diagnostic covariates.
Results
Patients and disposition
A total of 78 patients with RRMM were enrolled. All patients received ≥1 dose of study drug and were included in the safety population. Per protocol, seven patients from the safety lead-in cohort were included in the DLT-evaluable population and the pharmacokinetic-evaluable population. Patient demographics and baseline characteristics, including prior treatment exposure, are summarized in Table I . The median time from diagnosis was 53Á4 months (range 12Á9-142Á7). The mean age for the entire cohort was 63Á5 years (range 43-85); 37 were aged ≥65 years (47%). Overall, 51% of patients had International Staging System (ISS) stage II/III disease at the time of study entry, 62% had received 2/3 prior lines of therapy, 19% were refractory to at least one prior line, and 58%, 4%, 49% and 64% had received prior bortezomib, carfilzomib, lenalidomide and SCT, respectively; 17% of patients were immunomodulatory drug-naive.
At the time of data cut-off (29 June 2016), 54 patients (69%) had discontinued treatment, including 80% of patients aged <65 years (33/41) and 57% of those aged ≥65 years (21/ 37). PD was the primary reason for discontinuation in 29 patients (37%) [19 (46%) and 10 (27%) in patients aged <65 and ≥65 years, respectively]. Other reasons included AEs in 15 patients (19%), [9 (22%) and 6 (16%) in patients aged <65 and ≥65 years, respectively], patient withdrawal in five patients (6%) and other reasons in five patients (6%; other reasons were: proceeded to allogeneic transplantation, medically withdrawn due to lack of response, due to minor response, due to deterioration of performance status, and for radiation treatment for plasmacytoma, each n = 1). At data cut-off, 24 patients (31%) were ongoing on ICd therapy, including 8 aged <65 years (20%) and 16 aged ≥65 years (43%).
Efficacy
Five patients were excluded from the response-evaluable population. All five had no post-baseline assessment, and three of them also received less than two cycles of therapy. Reasons for discontinuation included AEs [n = 3; sepsis, cardiac arrest and cerebral haemorrhage (all considered not related to study drug)], withdrawn consent (n = 1) and PD (n = 1). Among 73 response-evaluable patients (n = 36, ≥65 years; n = 37, <65 years), the confirmed ORR was 48%, including 16% CR+VGPR (Table II) . ORR was 64% vs. 32%, including 25% vs. 8% CR+VGPR, in patients aged ≥65 years vs.
<65 years, respectively. Median times to first response were 1Á9, 2Á3 and 1Á9 months, respectively, for all evaluable patients, patients aged ≥65 and those aged <65 years (Figure S1 ). Median DOR was not reached for the overall population or for subgroups by age, with response durations of up to 17 months. Of patients with measurable M-protein at baseline (n = 73), 49% of patients achieved a ≥50% reduction (Fig 1) . Among the six patients (8%) with high-risk cytogenetic abnormalities, one patient achieved a VGPR, one achieved a PR and one achieved stable disease (SD) as their best response to treatment; the remaining three patients had PD with no documented response to treatment.
After a median follow-up of 15Á2 months, median PFS was 14Á2 months (Fig 2A) ; median PFS was 18Á7 months [95% confidence interval (CI), 11Á3, not estimable] vs. 12Á0 months (95% CI, 12Á0, not estimable) [hazard ratio (HR) = 0Á62, P = 0Á14] in patients aged ≥65 years vs. <65 years (Fig 2B) . The PFS benefit across patient subgroups is shown in Fig 2C. Among all patients, the estimated 18-month PFS rate was 47%, although patient numbers were small (n = 8); the probability of being event-free at 18 months was approximately 51% (n = 4) in patients aged ≥65 years and 37% (n = 4) in patients aged <65 years. A stepwise Cox model assessed potential predictive factors for PFS: age (≥65 years vs. <65 years), lines of prior therapy (1 vs. 2/3), creatinine clearance (≥60 ml/min vs. <60 ml/min), prior bortezomib exposure (exposed versus naive), prior immunomodulatory drug (exposed versus naive) and prior SCT (Yes versus No). Three covariates remained after adjustment as predictors of PFS; they were, in order of decreasing significance, age [HR = 0Á391 (95% CI, 0Á185, 0Á827), P = 0Á014], prior immunomodulatory drug exposure [HR = 3Á975 (95% CI, 1Á201, 13Á151), P = 0Á024] and prior SCT [HR = 0Á510 (95% CI, 0Á242, 1Á073), P = 0Á076].
Treatment exposure and safety profile
No DLTs occurred in the seven patients evaluated during the safety lead-in phase. At data cut-off, patients had received a median of 12 treatment cycles (range, 1-24); 44% had received ≥13 cycles of ixazomib. Among patients ≥65 and <65 years of age, the median treatment durations were 9 (range, 1-24) and 13 (range, 2-21) cycles, respectively. Median relative dose intensity (RDI) of each agent (defined as the proportion of the expected dose that was actually received) is shown in Table III . Median RDI was >90% for all agents, overall and in both age subgroups. Overall, ixazomib, cyclophosphamide and dexamethasone were dose modified in 70 (90%), 66 (85%) and 67 (86%) patients, respectively.
Overall, AEs occurred in 72 patients (92%), including 46 patients (59%) who experienced grade ≥3 AEs and 23 (29%) who had serious AEs (SAEs) ( Table III) . The most common any-grade treatment-emergent AEs were diarrhoea (33%), nausea (24%), upper respiratory tract infection (24%), thrombocytopenia (22%), neutropenia (21%) and Table IV) . The most common treatmentemergent grade ≥3 AEs were thrombocytopenia (15%), neutropenia (13%), anaemia (10%) and lymphopenia (6%) ( Table V) ; all other grade ≥3 AEs occurred in no more than three patients. SAEs were recorded in 23 patients (29%); SAEs of pneumonia, constipation, pyrexia, upper respiratory tract infection, thrombocytopenia and bronchitis each occurred in two patients. PN was reported in 10 patients (13%) overall (four with pre-existing PN), including three patients aged <65 years and seven aged ≥65 years. Six patients with a PN event had the first onset within 3 months after treatment initiation. PN events were all grade <3, except for one patient (<65 years) who had a grade 3 event that occurred between 12 and 15 months after treatment initiation. Of the 10 patients with PN, ixazomib dose was held for three patients, reduced for four patients, and the dose of all three study drugs was delayed for one patient. Among other AEs of interest, two patients had a thrombotic event and three patients had herpes zoster. Four patients (two aged <65 years, two aged ≥65 years) had arrhythmias (three had an underlying cardiac medical history at baseline). Two patients had heart failure; in one patient aged <65 years this was unrelated to study drug and resolved after medication and a procedure, and one patient aged ≥65 years had an underlying cardiac medical history. One patient (aged <65 years) with an underlying cardiac medical history had a myocardial infarction. Twelve patients (two aged <65 years and 10 aged ≥65 years) had a rash event; for most patients, the first occurrence was within the first 3 months after treatment initiation. There were no grade 4 rash events and no patient permanently discontinued study drug due to rash. There were four on-study deaths, due to cardiac arrest, severe pulmonary oedema, respiratory syncytial viral pneumonia and cerebral haemorrhage secondary to thrombocytopenia; the latter two were considered treatment-related.
Quality of life
Based on the EORTC QLQ-C30 questionnaire, the mean global health status/QoL score remained relatively constant in all patients, with small increases in mean scores observed at multiple time points ( Figure S2 ). Slight improvements in global health status/QoL score were observed for patients aged <65 years compared with patients aged ≥65 years, with the mean change from baseline being generally positive in patients aged <65 years compared with a small negative change from baseline in patients aged ≥65 years throughout the treatment period ( Figure S2 ). Similar to the overall global health status/ QoL scores, the subscale scores for physical functioning, role functioning, cognitive functioning, emotional functioning and social functioning were maintained in the overall population throughout the study (data not shown). The differences in mean EORTC QLQ-C30 subscale scores calculated from study entry to last measurement prior to PD in patients aged <65 years and patients aged ≥65 years are summarised in Table SI ; these data generally support the slight difference in QoL between patient age groups. Table III . Relative dose intensity and summary of safety profile for ICd.
All patients (N = 78)
Patients aged <65 years (n = 41) Patients aged ≥65 years (n = 37) (5) 1 (2) 3 (8) AE, adverse event; ICd, ixazomib, cyclophosphamide and dexamethasone; RDI, relative dose intensity; SAE, serious adverse event. *Deaths occurring within 30 days of last dose of study drug.
Ixazomib pharmacokinetics
Ixazomib was rapidly absorbed when administered in combination with cyclophosphamide and dexamethasone ( Figure S3) ; the median T max was 1Á23 h after day 1 administration and 2 h after day 15 administration. The geometric mean [% coefficient of variation (CV)] ixazomib maximum concentration and area under the concentrationtime curve (0-168 h) values after day 1 administration were 38Á2 (77) ng/ml and 514 (15) h*ng/ml, respectively. The corresponding values after day 15 administration were 42Á2 (76) ng/ml and 1120 (53) h*ng/ml, respectively. After multiple-dose administration, the geometric mean (% CV) terminal disposition stage half-life was 6Á1 (1Á1) days.
Discussion
Proteasome inhibitors remain an important part of the current treatment algorithm in RRMM (Lonial & Boise, 2011; Orlowski, 2011) . The introduction of ixazomib has allowed for the development of all-oral, PI-containing drug combinations, thus increasing convenience for patients while maintaining the efficacy associated with PIs. The improved safety profile of ixazomib versus bortezomib and carfilzomib, particularly with respect to the decreased incidence of PN (Moreau et al, 2012; Richardson, 2014; Kumar et al, 2017b; Richardson et al, 2017) and cardiac and renal events, respectively, also allows for longer-term use of ixazomib-based combinations compared with what had previously been feasible with PI-based combinations. Ixazomib in combination with lenalidomide and dexamethasone has been approved for the treatment of patients with MM who have received at least one prior therapy (https:// www.accessdata.fda.gov/drugsatfda_docs/label/2015/208462lbl. pdf). However, given the efficacy of PIs in combination with cyclophosphamide, as well as the potential for a lower-cost regimen containing only one novel agent, the efficacy and tolerability of ICd is of clinical interest. Cyclophosphamide is increasingly the alkylator of choice for multidrug combinations given the lower risk of haematological toxicity than with melphalan (Kumar et al, 2017c) . The combination of pomalidomide, cyclophosphamide and dexamethasone is being studied as an all-oral regimen combining an alkylator with a novel drug; in RRMM, ORRs of 50-91% have been reported (Larocca et al, 2013; Baz et al, 2016; Garderet et al, 2017) . Cyclophosphamide combinations with PIs as well as immunomodulatory drugs have been studied in the newly diagnosed setting as well as RRMM; however, to date, there is no all-oral regimen combining a PI and an alkylator. Here, we report promising efficacy for the all-oral ICd combination in patients with RRMM, with rapid onset of responses (median time to first response within two cycles of therapy, 1Á9 months) that deepened over the course of therapy and were durable, and a notable PFS benefit, thus offering an additional option for an ixazomib-based regimen in this setting. Although cross-trial comparisons can be confounded by differences in study designs, methods and patient populations, the ORR with ICd seen here, particularly in patients aged ≥65 years, is comparable with that seen with other regimens combining cyclophosphamide with novel agents in the relapsed setting (Kropff et al, 2007 (Kropff et al, , 2017 Schey et al, 2010; de Waal et al, 2015; Reece et al, 2016) . It is particularly difficult to directly compare the efficacy with that seen with VCd in this setting given that a large proportion of patients (58%) had received prior bortezomib. As might be expected, PFS was shorter among those patients with previous exposure to bortezomib (median PFS 12Á1 months vs. 16Á8 months). The impact of prior carfilzomib is hard to measure given the low frequency of carfilzomib exposure in this patient population.
When assessed according to age, patients aged ≥65 years had higher response rates as well as a trend towards better durability of response and prolonged PFS. Whereas our results clearly show that ICd is effective in older patients, it is important to note that many factors probably contributed to the difference between older and younger patients, including the lower rate of prior bortezomib exposure and prior transplant in the older subgroup as well as a lower proportion of patients with 2/3 prior lines of therapy. However, it should be noted that bortezomib exposure did not appear to be a predictive factor in the stepwise Cox analysis.
An important factor for sustained efficacy in older patients is the ability to maintain intensity of therapy. This is evidenced by the prolonged duration of therapy with ICd seen in the older patient population together with a relatively low discontinuation rate due to AEs, highlighting the good tolerability of the regimen. This is particularly important for elderly patients who often present with comorbidities and can be more susceptible to AEs and treatment complications, limiting their ability to tolerate the toxicity of certain drug regimens during prolonged therapy (Palumbo et al, 2011) .
The toxicity profile of the ICd combination was quite favourable, particularly in the older patients, with few discontinuations enabling prolonged use of the combination in this patient subset. The most common toxicities were haematological and likely to be related to both ixazomib and cyclophosphamide, with thrombocytopenia being a common AE with PIs in general and cyclophosphamide probably contributing to the neutropenia. The incidence of PN was substantially lower than that reported with bortezomib-based combinations and was mostly grade 1 or 2, decreasing the likelihood of discontinuation due to AEs. The incidence of gastrointestinal toxicity is consistent with that seen with ixazomib-based combinations in other trials in MM (Kumar et al, 2014a (Kumar et al, ,b, 2017b Richardson et al, 2014; Moreau et al, 2016) and, as evidenced by the low incidence of grade ≥3 events and discontinuations, these toxicities appear to be easily managed with supportive care approaches.
The overall tolerability of the ICd regimen is also evident from the global health status/QoL scores and the subscale scores, which demonstrate that patient-reported QoL was maintained during ICd treatment in both the young and elderly patient groups. Unlike in the newly diagnosed setting where improvements in QoL scores are expected (Niesvizky et al, 2015) , reflecting control of symptoms present at Table V . Most common grade ≥3 adverse events (AE) (occurring in ≥2 patients overall), overall and by age at study entry.
Grade ≥3 AE, n (%)
All patients (N = 78) Patients aged <65 years (n = 41) Patients aged ≥65 years (n = 37) diagnosis, in the relapsed setting patients are often asymptomatic at the time of initiation of therapy and hence one would not necessarily expect an improvement in scores. Pharmacokinetic data showed that ixazomib exposures were comparable to those reported previously in patients treated with ixazomib as a single agent (Kumar et al, 2014b; Gupta et al, 2017) and in combination with lenalidomide and dexamethasone (Kumar et al, 2014a; Gupta et al, 2017) , suggesting no pharmacokinetic interaction with cyclophosphamide and dexamethasone.
In summary, the combination of ixazomib, cyclophosphamide and dexamethasone is an effective, all-oral regimen for the treatment of RRMM, that builds on the synergy seen with PIs and alkylating agents. The favourable toxicity profile and the convenience of an all-oral regimen increases the value of this regimen, particularly for elderly patients. Furthermore, this combination appears suitable for the increasing number of patients who progress on lenalidomide maintenance. Future trials should examine the role of adding monoclonal antibodies to this backbone.
